Felix Grabherr

Felix Grabherr

Auto-generated profile, based on publicly available information

Felix Grabherr

Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
TATimon Adolph
Timon Adolph
MMMoritz Meyer
Moritz Meyer
JSJulian Schwärzler
Julian Schwärzler
LMLisa Mayr
Lisa Mayr
FGFelix Grabherr
Felix Grabherr
HTHerbert Tilg
Herbert Tilg

14 October 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
JSJiyeon Si
Jiyeon Si
JVJorge F. Vázquez-Castellanos
Jorge F. Vázquez-Castellanos
AGAnn C. Gregory
Ann C. Gregory
LDLindsey Decommer
Lindsey Decommer
LRLeen Rymenans
Leen Rymenans
JRJeroen Raes
Jeroen Raes
Extensive scientific and clinical microbiome studies have explored contemporary variation and dynamics of the gut microbiome in human health and disease1–3, yet the role of long-term life history effects has been underinvestigated. Here, we analyzed the current, quantitative microbiome composition in the older adult Bruneck Study cohort (Italians, Bruneck,n = 304 (male, 154; female, 150); age 65–98 years) with extensive clinical, demographic, lifestyle and nutritional data collected over the past 26 years4. Multivariate analysis of historical variables indicated that medication history, historical physical activity, past dietary habits and specific past laboratory blood parameters explain a significant fraction of current quantitative microbiome variation in older adults, enlarging the explanatory power of contemporary covariates by 33.4%. Prediction of current enterotype by a combination of past and contemporary host variables revealed good levels of predictability (area under the curve (AUC), 0.78–0.83), withPrevotellaand dysbioticBacteroides2 being the best predicted enterotypes. These findings demonstrate long-term life history effects on the microbiota and provide insights into lifestyle variables and their role in maintaining a healthy gut microbiota in later life.

22 November 2022 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
FGFelix Grabherr
Felix Grabherr
CGChristoph Grander
Christoph Grander
MEMaria Effenberger
Maria Effenberger
JSJulian Schwärzler
Julian Schwärzler
HTHerbert Tilg
Herbert Tilg
Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of alcohol-related liver disease (ALD), the new definition made its focus on the association of MAFLD with overweight/obesity, type 2 diabetes and metabolic risk factors especially also in normal weight/lean subjects. Several studies from the past 2 years have now used the new definition and have provided substantial information that this new definition might be accurate. Studies from the past 2 years have provided evidence that the new definition might be especially advantageous in the characterization and identification of patients with significant fibrosis. This has also been demonstrated in the well-known Rotterdam study in which the MAFLD-only group showed a higher rate of fibrosis and liver stiffness. MAFLD might also be able to predict all-cause mortality as demonstrated in the Third National Health and Nutrition Examination Survey. Furthermore, MAFLD might improve characterization of the cardiovascular risk of this patient population. As the term MAFLD has not yet been accepted universally, it remains important to coordinate efforts globally to adapt to this new definition and especially involve all specialities dealing with metabolic disorders such as diabetologists to further improve its definition and to prepare the medical community for its future use. The aim of this review is to summarize and critically address evidence emerging over the past 2 years that usage of the term MAFLD could be helpful in daily clinical practice.

29 November 2017 in Liver International
Verified
Journal Article
Closed access
PDF file
FGFelix Grabherr
Felix Grabherr
CGChristoph Grander
Christoph Grander
TATimon E. Adolph
Timon E. Adolph
VWVerena Wieser
Verena Wieser
LMLisa Mayr
Lisa Mayr
HTHerbert Tilg
Herbert Tilg

8 November 2018 in Journal of Obesity
Verified
Journal Article
Open access
PDF file
TATimon E. Adolph
Timon E. Adolph
FGFelix Grabherr
Felix Grabherr
LMLisa Mayr
Lisa Mayr
CGChristoph Grander
Christoph Grander
BEBarbara Enrich
Barbara Enrich
HTHerbert Tilg
Herbert Tilg
Introduction. Obesity and related nonalcoholic fatty liver disease (NAFLD) are an emerging health care issue that imposes substantial morbidity to individuals. Growth and differentiation factor 15 (GDF15) limits food uptake, body weight, and energy balance by modulation of GDNF-family receptor α-like (GFRAL) signalling in the hindbrain. However, the regulation of GDF15 expression in obesity and NAFLD is incompletely understood. We sought to define the impact of weight loss achieved by laparoscopic adjustable gastric banding (LAGB) on hepatic and adipose GDF15 expression in a cohort of severely obese patients. Methods. We analysed GDF15 expression of liver and subcutaneous adipose tissue before and 6 months after LAGB in severely obese patients undergoing LAGB by quantitative real-time PCR. To assess the role of inflammation on GDF15 expression, we analysed Hep G2 hepatocytes stimulated with cytokines such as IL-1β, TNFα, IL-6, LPS, or cellular stressors such as tunicamycin. Results. GDF15 expression was mostly confined to the liver compared to adipose tissue in severely obese patients. Weight loss induced by LAGB was associated with reduced hepatic (but not adipose tissue) expression of GDF15. Stimulation with IL-1β or tunicamycin induced hepatic GDF15 expression in hepatocytes. In line with this, hepatic GDF15 expression directly correlated with IL-1β expression and steatosis severity in NAFLD. These data demonstrated that amelioration of metabolic inflammation and weight loss reduced hepatic GDF15 expression. Conclusion. Based on recent mechanistic findings, our data suggest that hepatic GDF15 may serve as a negative feedback mechanism to control energy balance in NAFLD.

17 August 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MEMaria Effenberger
Maria Effenberger
Andreas KronbichlerAndreas Kronbichler
Andreas Kronbichler
EBErica Bettac
Erica Bettac
FGFelix Grabherr
Felix Grabherr
CGChristoph Grander
Christoph Grander
HTHerbert Tilg
Herbert Tilg
Background: Liver transplantation (LT) is the only curative treatment for end-stage liver disease. Less than 10% of global transplantation needs are met worldwide, and the need for LT is still increasing. The death rates on the waiting list remain too high. Objective: It is, therefore, critical to raise awareness among the public and health care providers and in turn increasingly acquire donors. Methods: We performed a Google Trends search using the search terms liver transplantation and liver transplant on October 15, 2020. On the basis of the resulting monthly data, the annual average Google Trends indices were calculated for the years 2004 to 2018. We not only investigated the trend worldwide but also used data from the United Network for Organ Sharing (UNOS), Spain, and Eurotransplant. Using pairwise Spearman correlations, Google Trends indices were examined over time and compared with the total number of liver transplants retrieved from the respective official websites of UNOS, the Organización Nacional de Trasplantes, and Eurotransplant. Results: From 2004 to 2018, there was a significant decrease in the worldwide Google Trends index from 78.2 in 2004 to 20.5 in 2018 (–71.2%). This trend was more evident in UNOS than in the Eurotransplant group. In the same period, the number of transplanted livers increased worldwide. The waiting list mortality rate was 31% for Eurotransplant and 29% for UNOS. However, in Spain, where there are excellent awareness programs, the Google Trends index remained stable over the years with comparable, increasing LT numbers but a significantly lower waiting list mortality (15%). Conclusions: Public awareness in LT has decreased significantly over the past two decades. Therefore, novel awareness programs should be initialized.